|
|
||||||||
CLINICAL STUDY |
Department of Medicine, Ryhov Hospital, 55185 Jönköping, Sweden, 1 Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden, 2 Department of Surgery, University Hospital, Linköping, Sweden, 3 Department of Medicine, Eskilstuna Hospital, Sweden, 4 Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Solna, Sweden, 5 Department of Endocrinology, Metabolism and Diabetology, Karolinska University Hospital, Huddinge, Sweden and 6 Department of Endocrinology and Diabetology, University Hospital, Lund, Sweden
(Correspondence should be addressed to B Bülow; Email: b.bulow{at}telia.com)
Objectives: To examine the risk of developing adrenal carcinomas and clinically overt hypersecreting tumours during short-term follow-up in patients with adrenal incidentalomas.
Design: 229 (98 males and 131 females) patients with adrenal incidentalomas were investigated in a prospective follow-up study (median time 25 months; range 3108 months). The patients were registered between January 1996 and July 2001 and followed until December 2004. Twenty-seven Swedish hospitals contributed with follow-up results.
Methods: Diagnostic procedures were undertaken according to a protocol including reinvestigation with computed tomography scans after 36 months, 1518 months and 2730 months, as well as hormonal evaluation at baseline and after 2730 months of follow-up. Operation was recommended when the incidentaloma size increased or if there was a suspicion of a hypersecreting tumour.
Results: The median age at diagnosis of the 229 patients included in the follow-up study was 64 years (range 2884 years) and the median size of the adrenal incidentalomas when discovered was 2.5 cm (range 18 cm). During the follow-up period, an increase in incidentaloma size of
0.5 cm was reported in 17 (7.4%) and of
1.0 cm was reported in 12 (5.2%) of the 229 patients. A decrease in size was seen in 12 patients (5.2%). A hypersecreting tumour was found in 2% of the hormonally investigated patients: Cushings syndrome (n = 2) and phaeochromocytoma (n = 1). Eleven patients underwent adrenalectomy, but no cases of primary adrenal malignancy were observed.
Conclusions: Patients with adrenal incidentaloma had a low risk of developing malignancy or hormonal hypersecretion during a short-term follow-up period.
This article has been cited by other articles:
![]() |
L. K. Nieman, B. M. K. Biller, J. W. Findling, J. Newell-Price, M. O. Savage, P. M. Stewart, and V. M. Montori The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1526 - 1540. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Weber and C. Eng Update on the Molecular Diagnosis of Endocrine Tumors: Toward -omics-Based Personalized Healthcare? J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1097 - 1104. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. F. Young Jr. The Incidentally Discovered Adrenal Mass N. Engl. J. Med., February 8, 2007; 356(6): 601 - 610. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |